ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LENZ vs OTLK // ENTERPRISE SCALE & MARKET CAP

LENZ Therapeutics Inc. (NASDAQ) VS. Outlook Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LENZ 3 — OTLK 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: OTLK
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LENZ VS. OTLK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LENZ OTLK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 96.00% 4.00% +92.00 LENZ /gross-margins <GO>
Return on Invested Capital (ROIC) -27.80% -35.00% +7.20 LENZ /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.19 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 LENZ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.8 37.0 -1.22 OTLK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $109.7M $120.1M -$10.5M OTLK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LENZ REV OTLK REV LENZ GROSS % OTLK GROSS % LENZ FCF OTLK FCF
FY 2025 $19.1M $1.4M 97.8% 4.0% -$70.0M -$51.8M
FY 2024 $0 $0 — — -$59.9M -$68.8M
FY 2023 $0 $0 — — -$60.4M -$43.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LENZ // BETA —
OTLK // BETA —